What is next in pharmacogenomics? Translating it to clinical practice

Pharmacogenomics

Volumn 4, Issue 4, 2003, Pages 499-505

  Valdes Jr , Roland ^a   Linder, Mark W ^a   Jortani, Saeed A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Guidelines; Laboratory medicine; Medical practice; Pharmacogenomics; Proteomics

Indexed keywords

ARTICLE; CLINICAL LABORATORY; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; GENETIC POLYMORPHISM; HEALTH CARE SYSTEM; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; PROTEIN POLYMORPHISM; PROTEOMICS;

HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL;

EID: 0038783606     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.4.499.22748     Document Type: Article

References (28)

1. Linder MW, Prough RA, Valdes R Jr: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43, 254-266 (1997).
2. Meadowcroft AM, Williamson KM, Patterson JH, Pieper JA: Pharmacogenetics and heart failure: a convergence with carvedilol. Pharmacotherapy 17, 637-639 (1997).
3. Anonymous: Pharmacogenomics at work. Nat. Biotech. 16, 885 (1998).
4. Sellers EM: Pharmacogenetics and ethnoracial differences in smoking. JAMA 280, 179-180 (1998).
5. Tanaka E, Misawa S: Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines and tricyclic and tetracyclic antidepressants - an update. J. Clin. Pharm. Ther. 23, 331-336 (1998).
6. Caraco Y: Genetic determinants of drug responsiveness and drug interactions. Ther. Drug Monit. 20, 517-24 (1998).
7. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
8. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
9. Ross JS, Ginsburg GS: The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice. Amer. J. Clin. Pathol. 119(1), 26-36 (2003).
10. Shi MM: Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin. Chem. 47(2), 164-172 (2001).
11. Valdes R Jr, Jortani SA: The current assessment of qualitative and quantitative point-of-care delivery of cardiac markers. In: Markers in Cardiology: Current and Future Clinical Applications. Adams JE III, Apple FS, Jaffe AS, WU AHB (Eds). Armonk, NY: Futura Publishing Company, Inc. 35-46 (2001).
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al.: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem. 49, 7-18 (2003).
13. Freeman B, Zehnbauer B, McGrath S: Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128, 281-5 (2000).
14. Ulrich CM, Robien K, Sparks R: Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 3, 299-313 (2002).
15. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin. Chem. 48, 436-472 (2002).
16. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB: Diagnosis and monitoring of hepatic injury II. Recommendations for use of laboratory tests in screening, diagnosis and monitoring. Clin. Chem. 46, 2050-2068 (2000).
17. Weinstein JN: 'Omic'and hypothesis-driven research in molecular pharmacology of cancer. Curr. Opin. Pharmacol. 2, 361-365 (2002).
18. Kratz A, Januzzi JL, Lewandrowski KB, Lee-Lewandrowski E: Positive predictive value of a point-of-care testing strategy on first-draw specimens for the emergency department-based detection of acute coronary syndromes. Arch. Pathol. Lab. Med. 126, 1487-1493 (2002).
19. Markey K, Axel L, Ahnen D: Basic concepts for genetic testing in common hereditary colorectal cancer syndromes. Curr. Gastroenterol. Reports 4, 404-413 (2002).
20. Dare TO, Davies HA, Turton JA, Lomas L, Williams TC, York MJ: Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. Electrophoresis 23(18), 3241-3251 (2002).
21. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC: Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl. Acad. Sci. 95, 1148-1153 (1998).
22. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukaemia. Blood 100, 3832-3834 (2002).
23. Linder MW, Valdes R Jr: Genetic mechanisms for variability in drug response and toxicity. J. Anal. Toxicol. 25, 405-413 (2001).
24. Tirona RG, Leake BF, Merino G, Min RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
25. Zychma MJ, Gumprecht J, Strojek K, Grzeszczak W, Moczulski D, Trautsolt W et al.: Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in Type 2 diabetic subjects. Med. Sci. Monitor 8, CR512-515 (2002).
26. Kinjo Y, Takasu N, Komiya I, Tomoyose T, Takara M, Kouki T et al.: Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J. Clin. Endocrinol. Metab. 87(6), 2593-2596 (2002).
27. Garry PJ, Baumgartner RN, Brodie SG, Montoya GD, Liang HC, Lindeman RD et al.: Oestrogen replacement therapy, serum lipids and polymorphism of the apolipoprotein E gene. Clin. Chem. 45, 1214-1223 (1999).
28. Van Loon JA, Szumlanski CL, Weinshilboum RM: Human kidney thiopurine methyltransferase. Photoaffinity labelling with S-adenosyl-L-methionine. Biochem. Pharmacol. 44, 775-785 (1992).